Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most broad bleeding-risk and GI-bleeding concepts align with the NSAID boxed warning/warnings for CALDOLOR (ibuprofen). However, multiple claims about duloxetine-specific platelet/serotonin mechanisms, duloxetine-NSAID interaction being specific to duloxetine rather than class effect, duloxetine side effects, and acetaminophen being universally lower-bleeding-risk are not supported by the provided ibuprofen (CALDOLOR) label excerpts.
Category Scores
Accurate Statements
The label for CALDOLOR (ibuprofen) states NSAIDs increase the risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation (which can be fatal).
BOXED WARNING; 5.2
NSAIDs/ibuprofen can cause serious GI adverse events that can occur at any time and without warning symptoms.
5.2
Elderly patients are at greater risk for NSAID-associated serious GI events.
8.5 (Geriatric Use)
CALDOLOR labeling identifies bleeding risk with concomitant anticoagulants such as warfarin (synergistic effect on bleeding).
Table 3: Clinically Significant Drug Interactions with Ibuprofen; anticoagulants such as warfarin
CALDOLOR labeling notes increased bleeding risk with interference with antiplatelet activity of aspirin and that concomitant use of CALDOLOR with analgesic doses of aspirin is not generally recommended due to increased bleeding risk.
Table 3: Clinically Significant Drug Interactions with Ibuprofen; aspirin interference; not generally recommended with analgesic doses
Unsupported Statements
Cymbalta (duloxetine) can increase bleeding risk.
Provided FDA label excerpts are for CALDOLOR (ibuprofen injection) only; no duloxetine-specific bleeding risk is supported in the supplied text.
Duloxetine-related side effects to watch for include worsening nausea, dizziness, or changes in mood.
No duloxetine adverse effect information is present in the supplied ibuprofen (CALDOLOR) prescribing information excerpts.
Duloxetine can affect platelet function through serotonin pathways.
No duloxetine mechanism or platelet/serotonin pathway discussion is supported in the supplied CALDOLOR label excerpts.
Ibuprofen does not cause worsening nausea, dizziness, or changes in mood directly.
The supplied labeling excerpts do not address ibuprofen-specific claims about nausea/dizziness/mood causality.
Higher doses of ibuprofen and longer use generally increase gastrointestinal and bleeding risk when combined with duloxetine.
While the ibuprofen boxed warning/5.2 address duration-related risk in general terms (and 5.1 explicitly for CV risk), the provided text does not support a duloxetine-specific combined-risk statement.
Acute short-term pain relief with ibuprofen generally has a lower risk than frequent or high-dose use, but the combination still warrants caution when used with duloxetine.
The provided ibuprofen label excerpts state that even short-term therapy is not without risk, and do not support a duloxetine-combination relative risk comparison.
Duloxetine can make bleeding more likely when an NSAID is added.
No duloxetine-specific interaction/bleeding statement is supported by the provided ibuprofen label excerpts.
In cases of a history of stomach ulcers or GI bleeding, use of blood thinners, or use of other medicines that affect bleeding, clinicians often avoid NSAIDs or monitor more closely.
The supplied excerpts do not support this as a general clinician practice statement.
For many people on duloxetine, acetaminophen is considered a lower-bleeding-risk option than ibuprofen.
No acetaminophen comparative bleeding-risk guidance is present in the supplied CALDOLOR labeling excerpts.
Contradictions
Important Omissions
If the claims are intended to address CALDOLOR/ibuprofen safety, the label excerpts provided do not support patient guidance about duloxetine-specific interaction signs (e.g., bruising) being tied to duloxetine specifically; instead, the label excerpts support reporting GI bleeding symptoms and cardiovascular symptoms for NSAID/CALDOLOR.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some class-based NSAID GI-bleeding/serious bleeding risk concepts align with the CALDOLOR boxed warning and warnings. However, multiple duloxetine-specific mechanistic and interaction claims are unsupported by the provided ibuprofen prescribing information, which could mislead about which drug drives the risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Numerous claims attribute bleeding/platelet/serotonin and adverse effect details to duloxetine and duloxetine+NSAID combination effects without support from the provided CALDOLOR (ibuprofen injection) label excerpts.
Suggested Improvement
Restrict statements to what the ibuprofen (CALDOLOR) label supports: NSAID-associated serious GI bleeding/ulceration/perforation, timing (can occur at any time; even short-term not without risk), and label-supported interactions with anticoagulants/aspirin where excerpts are provided. Remove or qualify duloxetine-specific mechanism and duloxetine-combination-specific risk assertions unless duloxetine labeling is provided.